Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Rendell, Aimee; Thomas-Bland, Isobel; McCuish, Lee; Taylor, Christopher; Binju, Mudra; Yu, Yu

Rendell, Aimee; Thomas-Bland, Isobel; McCuish, Lee; Taylor, Christopher; Binju, Mudra; Yu, Yu.

Afiliação

Rendell A; Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia.
Thomas-Bland I; Faculty of Health Sciences, Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA 6102, Australia.
McCuish L; Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia.
Taylor C; Faculty of Health Sciences, Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA 6102, Australia.
Binju M; Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia.
Yu Y; Faculty of Health Sciences, Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA 6102, Australia.

Biomedicines ; 10(9)2022 Aug 29.

Article em En | MEDLINE | ID: mdl-36140214

Palavras-chave

cancer vaccine; kinase inhibitors; ovarian cancer; platinum resistance; recurrent cancers; tyrosine kinases

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Biomedicines Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google